TY - JOUR
T1 - An interdomain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcription
AU - Badtke, Matthew P.
AU - Khan, Irfan
AU - Cao, Feng
AU - Hu, Jianming
AU - Tavis, John E.
N1 - Funding Information:
This work was supported by NIH grants AI38447 to J.E.T. and AI043453 to J.H.
PY - 2009/7/20
Y1 - 2009/7/20
N2 - The T3 motif on the duck hepatitis B virus reverse transcriptase (P) is proposed to be a binding site essential for viral replication, but its ligand and roles in DNA synthesis are unknown. Here, we found that T3 is needed for P to bind the viral RNA, the first step in DNA synthesis. A second motif, RT-1, was predicted to assist T3. T3 and RT-1 appear to form a composite RNA binding site because mutating T3 and RT-1 had similar effects on RNA binding, exposure of antibody epitopes on P, and DNA synthesis. The T3 and RT-1 motifs bound RNA non-specifically, yet they were essential for specific interactions between P and the viral RNA. This implies that specificity for the viral RNA is provided by a post-binding step. The T3:RT-1 motifs are conserved with the human hepatitis B virus and may be an attractive target for novel antiviral drug development.
AB - The T3 motif on the duck hepatitis B virus reverse transcriptase (P) is proposed to be a binding site essential for viral replication, but its ligand and roles in DNA synthesis are unknown. Here, we found that T3 is needed for P to bind the viral RNA, the first step in DNA synthesis. A second motif, RT-1, was predicted to assist T3. T3 and RT-1 appear to form a composite RNA binding site because mutating T3 and RT-1 had similar effects on RNA binding, exposure of antibody epitopes on P, and DNA synthesis. The T3 and RT-1 motifs bound RNA non-specifically, yet they were essential for specific interactions between P and the viral RNA. This implies that specificity for the viral RNA is provided by a post-binding step. The T3:RT-1 motifs are conserved with the human hepatitis B virus and may be an attractive target for novel antiviral drug development.
UR - http://www.scopus.com/inward/record.url?scp=67649479264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649479264&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2009.04.023
DO - 10.1016/j.virol.2009.04.023
M3 - Article
C2 - 19467554
AN - SCOPUS:67649479264
SN - 0042-6822
VL - 390
SP - 130
EP - 138
JO - Virology
JF - Virology
IS - 1
ER -